Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0C2NK
|
||||
| Former ID |
DIB020562
|
||||
| Drug Name |
norfluoxetine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H16F3NO
|
||||
| InChI |
InChI=1S/C16H16F3NO/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12/h1-9,15H,10-11,20H2
|
||||
| InChIKey |
WIQRCHMSJFFONW-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
515992, 841245, 3249471, 4712768, 8152798, 14849332, 29223632, 50066100, 50707944, 57322322, 85209721, 92729852, 99443277, 103131848, 103556000, 104306700, 117505046, 125607181, 125812945, 126665903, 129587205, 135062212, 135371955, 135650734, 137016413, 141566791, 152050510, 160967894, 162919696, 163640919, 179293685, 184565588, 184605154, 223682774, 223809731, 225228000, 226980400, 249897421, 252236770, 252355234
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 2B receptor | Target Info | Antagonist | [2] | |
| 5-hydroxytryptamine 2A receptor | Target Info | Antagonist | [2] | ||
| 5-hydroxytryptamine 2C receptor | Target Info | Antagonist | [2] | ||
| Kv3.1 | Target Info | Inhibitor (gating inhibitor) | [3] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channelshsa04020:Calcium signaling pathway | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | 5HT2 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (q) signalling eventsR-HSA-390666:Serotonin receptors | |||||
| G alpha (q) signalling events | |||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling | |||||
| SIDS Susceptibility Pathways | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 208). | ||||
| REF 2 | Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41. | ||||
| REF 3 | Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1. Neuropharmacology. 2001 Sep;41(4):443-53. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.